Logo image of XERS

XERIS BIOPHARMA HOLDINGS INC (XERS) Stock Fundamental Analysis

NASDAQ:XERS - Nasdaq - US98422E1038 - Common Stock - Currency: USD

4.35  -0.07 (-1.58%)

After market: 4.33 -0.02 (-0.46%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to XERS. XERS was compared to 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of XERS have multiple concerns. XERS is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year XERS has reported negative net income.
In the past year XERS has reported a negative cash flow from operations.
XERS had negative earnings in each of the past 5 years.
XERS had a negative operating cash flow in each of the past 5 years.
XERS Yearly Net Income VS EBIT VS OCF VS FCFXERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

XERS's Return On Assets of -14.29% is fine compared to the rest of the industry. XERS outperforms 66.67% of its industry peers.
Industry RankSector Rank
ROA -14.29%
ROE N/A
ROIC N/A
ROA(3y)-21.25%
ROA(5y)-32.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XERS Yearly ROA, ROE, ROICXERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

The Gross Margin of XERS (82.21%) is better than 87.69% of its industry peers.
XERS's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for XERS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.81%
GM growth 5Y14.98%
XERS Yearly Profit, Operating, Gross MarginsXERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

1

2. Health

2.1 Basic Checks

XERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XERS has been increased compared to 1 year ago.
The number of shares outstanding for XERS has been increased compared to 5 years ago.
Compared to 1 year ago, XERS has a worse debt to assets ratio.
XERS Yearly Shares OutstandingXERS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
XERS Yearly Total Debt VS Total AssetsXERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -1.08, we must say that XERS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of XERS (-1.08) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.08
ROIC/WACCN/A
WACC11.09%
XERS Yearly LT Debt VS Equity VS FCFXERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

XERS has a Current Ratio of 1.72. This is a normal value and indicates that XERS is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.72, XERS is not doing good in the industry: 66.15% of the companies in the same industry are doing better.
A Quick Ratio of 1.17 indicates that XERS should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.17, XERS is not doing good in the industry: 70.26% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.72
Quick Ratio 1.17
XERS Yearly Current Assets VS Current LiabilitesXERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.17% over the past year.
Looking at the last year, XERS shows a very strong growth in Revenue. The Revenue has grown by 29.87%.
The Revenue has been growing by 137.28% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)36.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
Revenue 1Y (TTM)29.87%
Revenue growth 3Y59.98%
Revenue growth 5Y137.28%
Sales Q2Q%47.94%

3.2 Future

Based on estimates for the next years, XERS will show a very strong growth in Earnings Per Share. The EPS will grow by 34.91% on average per year.
XERS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.01% yearly.
EPS Next Y86.58%
EPS Next 2Y50.39%
EPS Next 3Y43.25%
EPS Next 5Y34.91%
Revenue Next Year33.57%
Revenue Next 2Y25.6%
Revenue Next 3Y22.47%
Revenue Next 5Y22.01%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
XERS Yearly Revenue VS EstimatesXERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
XERS Yearly EPS VS EstimatesXERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XERS. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 43.74, which means the current valuation is very expensive for XERS.
Based on the Price/Forward Earnings ratio, XERS is valued a bit cheaper than 70.26% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of XERS to the average of the S&P500 Index (22.13), we can say XERS is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 43.74
XERS Price Earnings VS Forward Price EarningsXERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XERS Per share dataXERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as XERS's earnings are expected to grow with 43.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.39%
EPS Next 3Y43.25%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XERS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XERIS BIOPHARMA HOLDINGS INC

NASDAQ:XERS (6/13/2025, 8:00:02 PM)

After market: 4.33 -0.02 (-0.46%)

4.35

-0.07 (-1.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners43.73%
Inst Owner Change35.33%
Ins Owners3.43%
Ins Owner Change5.53%
Market Cap696.70M
Analysts85
Price Target6.55 (50.57%)
Short Float %11.59%
Short Ratio6.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.63%
Min EPS beat(2)-10.3%
Max EPS beat(2)53.56%
EPS beat(4)2
Avg EPS beat(4)7.88%
Min EPS beat(4)-19.83%
Max EPS beat(4)53.56%
EPS beat(8)3
Avg EPS beat(8)3.77%
EPS beat(12)7
Avg EPS beat(12)10.13%
EPS beat(16)8
Avg EPS beat(16)1.19%
Revenue beat(2)2
Avg Revenue beat(2)1.86%
Min Revenue beat(2)1.41%
Max Revenue beat(2)2.31%
Revenue beat(4)4
Avg Revenue beat(4)2.51%
Min Revenue beat(4)1.41%
Max Revenue beat(4)3.44%
Revenue beat(8)6
Avg Revenue beat(8)3.44%
Revenue beat(12)9
Avg Revenue beat(12)2.94%
Revenue beat(16)10
Avg Revenue beat(16)1.75%
PT rev (1m)2.67%
PT rev (3m)25.82%
EPS NQ rev (1m)35.71%
EPS NQ rev (3m)51.79%
EPS NY rev (1m)36.17%
EPS NY rev (3m)76.56%
Revenue NQ rev (1m)3.07%
Revenue NQ rev (3m)9.02%
Revenue NY rev (1m)2.06%
Revenue NY rev (3m)11.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 43.74
P/S 3.13
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.3
EYN/A
EPS(NY)0.1
Fwd EY2.29%
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS1.39
BVpS-0.22
TBVpS-0.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.29%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.21%
FCFM N/A
ROA(3y)-21.25%
ROA(5y)-32.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.81%
GM growth 5Y14.98%
F-Score4
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.63%
Cap/Sales 0.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.72
Quick Ratio 1.17
Altman-Z -1.08
F-Score4
WACC11.09%
ROIC/WACCN/A
Cap/Depr(3y)9.44%
Cap/Depr(5y)22.43%
Cap/Sales(3y)0.76%
Cap/Sales(5y)1.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
EPS Next Y86.58%
EPS Next 2Y50.39%
EPS Next 3Y43.25%
EPS Next 5Y34.91%
Revenue 1Y (TTM)29.87%
Revenue growth 3Y59.98%
Revenue growth 5Y137.28%
Sales Q2Q%47.94%
Revenue Next Year33.57%
Revenue Next 2Y25.6%
Revenue Next 3Y22.47%
Revenue Next 5Y22.01%
EBIT growth 1Y49.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year179.53%
EBIT Next 3Y69.48%
EBIT Next 5Y46.27%
FCF growth 1Y66.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.87%
OCF growth 3YN/A
OCF growth 5YN/A